Discontinued Operations

12 Months Ended

Aug. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

NOTE 5 – DISCONTINUED OPERATIONS

During October 2013 the Company’s management and Board of Directors determined to dispose of Oncologix Corporation its Brachytherapy medical device subsidiary. On November 1, 2013, the company entered into a settlement agreement with Firetag, Stoss & Dowdell, PC., our former attorneys. Per the terms of the settlement agreement, we exchanged our 90% ownership and executed a $50,000 promissory note payable to Firetag in exchange for the forgiveness by Firetag of $145,522 in prior legal billings. The promissory note bears interest at 4% and requires 12 monthly payments of $4,257.49 beginning on December 1, 2013. Detailed below are the income and expenses related to these discontinued operations:

	For the year ended
	August 31,			August 31,
	2014			2013
Operating expenses:
General and administrative	$	36		$	14
Depreciation and amortization		—			—
Total operating expenses		36			14
Loss from operations		(36	)		(14	)
Other income (expense):
Total other income (expense)		—			—
Loss from discontinued operations		(36	)		(14	)
Gain on disposal of discontinued operations		95,564			—
Loss from discontinued operations		95,528			(14	)
Less loss attributable to noncontrolling interest		—			—
Net loss from discontinued operations	$	95,528		$	(14	)